Novartis Heart Drug Fails Phase 3 Trial: Cutting Genetic Cholesterol Marker Fails to Stop Cardiac Attacks

Swiss pharmaceutical giant Novartis has reported a major setback in global cardiology after its experimental heart drug pelacarsen failed its late-stage clinical trial, leaving researchers questioning long-held theories on genetic cholesterol.

Data from the landmark Phase 3 Lp(a)HORIZON trial showed that while pelacarsen successfully slashed blood levels of lipoprotein(a) by up to 80%, it failed to reduce the actual incidence of heart attacks, strokes, or cardiac deaths among patients. The findings present a paradox for medical science: a treatment can fix a dangerous lab reading without delivering real-world protection to human lives.

Lipoprotein(a), commonly referred to as Lp(a), is a genetically inherited, sticky variant of cholesterol affecting nearly 20% of the global population. Indian demographics remain particularly vulnerable, with studies suggesting South Asians face higher baseline rates of premature heart disease linked to elevated Lp(a) levels.

The Biomarker Paradox That Stunned Cardiologists

Novartis designed pelacarsen using advanced RNA technology to target the genetic source of Lp(a) production in the liver. In laboratory measurements, the injection worked exactly as planned, driving down circulating levels of the high-risk lipid particle across thousands of trial participants.

The ultimate measure of any cardiovascular drug relies on patient outcomes rather than blood work. Over the course of the 8,300-patient international trial, individuals receiving pelacarsen suffered major adverse cardiovascular events at almost the exact same rate as those given a placebo alongside standard medical care.

Medical experts monitoring the trial outcome noted that clearing a dangerous blood marker late in a patient's life cannot simply erase decades of existing arterial scarring. Once structural damage settles into cardiac blood vessels, removing the initial trigger may offer limited therapeutic relief.

Standard Bad Cholesterol Rules Still Apply

Cardiologists have rushed to reassure heart patients that this setback does not challenge existing treatments for traditional "bad cholesterol" or low-density lipoprotein (LDL).

Robust clinical evidence spanning several decades proves that lowering standard LDL cholesterol using widely prescribed statins, ezetimibe, or PCSK9 inhibitors directly lowers the risk of heart failure and arterial blockages. The failure of pelacarsen remains isolated strictly to the removal of the specific Lp(a) protein in individuals who already live with established heart conditions.

Patients currently taking prescribed cholesterol medication are urged to continue their daily regimen. Managing traditional LDL cholesterol, maintaining optimal blood pressure, and keeping blood sugar levels balanced remain the most reliable defenses against heart disease.

High Stakes for Rival Global Drugmakers

The trial result has cast a shadow over competing global drugmakers, including US-based biopharma firms Amgen and Eli Lilly. Both companies are spending millions of dollars on late-stage clinical trials for their own Lp(a)-lowering candidates, olpasiran and lepodisiran.

Industry analysts point out that rival therapies achieve deeper biological suppression, knocking down Lp(a) levels by more than 90 to 95%. Researchers now face an urgent question: does stopping heart attacks require a near-total elimination of the protein, or is targeting Lp(a) after heart disease sets in an entirely flawed strategy?

For millions of patients navigating hereditary heart risks, the search for a proven therapeutic solution continues as medical regulators examine the full dataset from the Novartis trial.